Hepatitis C Treatment Cascade in a Federally Qualified Health Center
- PMID: 31512110
- DOI: 10.1007/s10900-019-00736-4
Hepatitis C Treatment Cascade in a Federally Qualified Health Center
Abstract
Hepatitis C (HCV) care cascades have been described in diverse clinical settings, patient populations and countries, highlighting the steps in HCV care where improvements can be made and resources allocated. However, more research is needed to examine barriers to HCV treatment in rural, underserved populations and in Federally Qualified Health Centers (FQHCs). As part of a quality improvement (QI) project, this study aimed to describe and evaluate the HCV treatment cascade in an FQHC serving a large rural patient population in the Western United States. Standardized chart abstraction was utilized to aggregate data regarding patient demographics, the percentage of patients achieving each step in the treatment cascade, and relevant patient (i.e., viral load) and service variables (i.e., whether and when patients received treatment or medication). 389 patients were identified as having HCV and 86% were aware of their diagnosis. Fifty-five percent had their infection confirmed via viral load, 21% were staged for liver disease, 24% received a prescription for treatment, and 19% achieved cure. Compared to national data, the current regional sample had greater rates of diagnosis awareness and access to care, as well as sustained virologic response (SVR), but lower rates of viral load confirmation. Current findings suggest that rural patients living with HCV who receive care at FQHCs struggle to navigate the treatment cascade and achieve a cure, particularly with regard to infection confirmation, liver staging, and prescription. However, compared to national estimates, patients had greater rates of diagnosis awareness/treatment access and SVR.
Keywords: Care cascade; Federally Qualified Health Center; Hepatitis C; Quality improvement; Rural health.
Similar articles
-
A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities.J Prim Care Community Health. 2018 Jan-Dec;9:2150132718807520. doi: 10.1177/2150132718807520. J Prim Care Community Health. 2018. PMID: 30348039 Free PMC article.
-
Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center.J Am Pharm Assoc (2003). 2022 Sep-Oct;62(5):1596-1605. doi: 10.1016/j.japh.2022.04.014. Epub 2022 Apr 26. J Am Pharm Assoc (2003). 2022. PMID: 35595639
-
Spatial availability of federally qualified health centers and disparities in health services utilization in medically underserved areas.Soc Sci Med. 2023 Jul;328:116009. doi: 10.1016/j.socscimed.2023.116009. Epub 2023 Jun 2. Soc Sci Med. 2023. PMID: 37301106
-
Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002.Clin Liver Dis. 2003 Feb;7(1):261-87. doi: 10.1016/s1089-3261(02)00078-8. Clin Liver Dis. 2003. PMID: 12691470 Review.
-
Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.Pharmacotherapy. 2016 Feb;36(2):203-17. doi: 10.1002/phar.1700. Epub 2016 Feb 5. Pharmacotherapy. 2016. PMID: 26846728 Review.
Cited by
-
Impact of a Pharmacist-Led HCV Treatment Program at a Federally Qualified Health Center.Pharmacy (Basel). 2024 Jul 24;12(4):115. doi: 10.3390/pharmacy12040115. Pharmacy (Basel). 2024. PMID: 39195844 Free PMC article.
-
Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region.J Infect Dis. 2020 Sep 2;222(Suppl 5):S354-S364. doi: 10.1093/infdis/jiaa141. J Infect Dis. 2020. PMID: 32877562 Free PMC article.
-
Cascade of Care for Hepatitis C Virus Infection Among Young Adults Who Inject Drugs in a Rural County in New Mexico.Public Health Rep. 2023 Nov-Dec;138(6):936-943. doi: 10.1177/00333549221143086. Epub 2023 Jan 12. Public Health Rep. 2023. PMID: 36633367 Free PMC article.
-
High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.PLoS One. 2021 May 6;16(5):e0251158. doi: 10.1371/journal.pone.0251158. eCollection 2021. PLoS One. 2021. PMID: 33956867 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials